Activity of nsp14 Exonuclease from SARS-CoV-2 towards RNAs with Modified 3'-Termini

Dokl Biochem Biophys. 2023 Apr;509(1):65-69. doi: 10.1134/S1607672923700102. Epub 2023 Jun 20.

Abstract

The COVID-19 pandemic has shown the urgent need for new treatments for coronavirus infections. Nucleoside analogs were successfully used to inhibit replication of some viruses through the incorporation into the growing DNA or RNA chain. However, the replicative machinery of coronaviruses contains nsp14, a non-structural protein with a 3'→5'-exonuclease activity that removes misincorporated and modified nucleotides from the 3' end of the growing RNA chain. Here, we studied the efficiency of hydrolysis of RNA containing various modifications in the 3'-terminal region by SARS-CoV-2 nsp14 exonuclease and its complex with the auxiliary protein nsp10. Single-stranded RNA was a preferable substrate compared to double-stranded RNA, which is consistent with the model of transfer of the substrate strand to the exonuclease active site, which was proposed on the basis of structural analysis. Modifications of the phosphodiester bond between the penultimate and last nucleotides had the greatest effect on nsp14 activity.

Keywords: RNA oligonucleotides; antiviral drugs; coronaviruses; exonucleases; nsp10; nsp14; nucleoside inhibitors; replication proofreading.

MeSH terms

  • Antiviral Agents / chemistry
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • COVID-19*
  • Exonucleases
  • Humans
  • Nucleotides
  • Pandemics
  • RNA, Viral / genetics
  • SARS-CoV-2* / genetics
  • Virus Replication / genetics

Substances

  • Exonucleases
  • RNA, Viral
  • Nucleotides
  • Antiviral Agents